STOCK TITAN

Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Palatin Technologies (PTN) presented preclinical results for its MC4R-selective peptide programs at ObesityWeek 2026 and selected PL2001 for clinical development. The compounds showed greater than 100-fold to greater than 200-fold selectivity for MC4R over MC1R in functional assays. PL1002 and PL2001 reduced body weight and food intake in diet-induced obese mice in a dose-dependent manner.

Lipidated peptides had an approximately 24-hour half-life in rodents and greater than 168 hours in dogs, versus approximately two hours for non-lipidated selective peptides. Palatin sees potential for once-weekly or less frequent injections and reduced skin darkening. PL1001 showed no observed heart-rate or blood-pressure effects at the efficacious doses and time points evaluated. PL2001 preparation activities are progressing, with first-in-human studies targeted for the first half of 2027 and initial clinical data anticipated in the second half.

Loading...
Loading translation...
11 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointPL2001 selected for clinical development; regulatory-enabling and chemistry, manufacturing, and controls activities are progressing.
  • Minor pointPeptides demonstrated greater than 100-fold to greater than 200-fold MC4R-over-MC1R selectivity in functional assays.
  • Minor pointPL1002 produced significant, dose-dependent weight and food-intake reductions in diet-induced obese mice with twice-daily administration.
  • Minor pointPL2001 produced significant, dose-dependent weight and food-intake reductions in diet-induced obese mice after one subcutaneous dose.
  • Minor pointLipidated peptides showed half-lives of approximately 24 hours in rodents and greater than 168 hours in dogs, versus approximately two hours for non-lipidated selective peptides.
6 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Once-weekly or less frequent injections are a potential dosing approach supported by the preclinical findings, Palatin said.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Minimal to no MC1R activity in vitro supports potential reduction or elimination of skin darkening, Palatin said.
  • Minor pointPL1001 showed no observed heart-rate or blood-pressure effects at the efficacious doses and time points evaluated preclinically.
  • Minor point. Forward-looking: it has not happened yet and may not happen.First-in-human studies targeted for first-half 2027, with initial clinical data anticipated in second-half 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Additional cardiovascular safety studies are planned to further characterize the compounds.
  • Minor pointOral MC4R-selective peptide development continues alongside Palatin's oral small-molecule MC4R agonist program.

Negative

  • None.

Key Figures

MC4R selectivity over MC1R: Greater than 100-fold to greater than 200-fold Lipidated peptide half-life: Approximately 24 hours Lipidated peptide half-life: Greater than 168 hours +4 more
MC4R selectivity over MC1R
Greater than 100-fold to greater than 200-fold
Reported functional assays
Lipidated peptide half-life
Approximately 24 hours
Preclinical pharmacokinetic studies in rodents
Lipidated peptide half-life
Greater than 168 hours
Preclinical pharmacokinetic studies in dogs
Non-lipidated peptide half-life
Approximately two hours
Preclinical comparison
Potential dosing frequency
Once-weekly or less frequent
Potential subcutaneous administration
First-in-human studies
First half of calendar 2027
Targeted timing for PL2001
Initial clinical data
Second half of 2027
Anticipated timing

Historical Context

1 past event · Latest: Sep 28
1 event
  1. Sep 28

    FY26 results

    24h Move
    -5.1%

    FY26 results disclosed cash runway concerns while retaining a first-half 2027 MC4R study target

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

mc4r, mc1r, pharmacokinetic, subcutaneous, +1 more
5 terms
mc4r medical
"potent MC4R activity with minimal to no MC1R activity"
mc4r is a gene that makes a protein in the brain acting like a thermostat for appetite and energy use; when it works normally it helps signal when to eat and when to stop. It matters to investors because changes in this gene or drugs that target its protein can alter obesity and metabolic disease outcomes, influencing clinical trial results, regulatory approvals, and the commercial prospects of therapies.
mc1r medical
"minimal to no MC1R activity in vitro"
MC1R is a human gene that encodes a protein on cell surfaces involved in skin and hair pigmentation and in cellular responses to ultraviolet light. For investors, changes or mutations in MC1R matter because they can influence disease risk (notably certain skin cancers), be used as biomarkers, or serve as targets for diagnostics and therapies—think of it as a control switch that drug developers or diagnostic companies might aim to measure or modify.
pharmacokinetic medical
"Preclinical pharmacokinetic studies demonstrated an approximately 24-hour half-life"
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.
subcutaneous medical
"once-weekly or less frequent subcutaneous administration"
Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.
cmc technical
"chemistry, manufacturing, and controls (CMC) activities are progressing"
Chemistry, Manufacturing, and Controls (CMC) describes the technical documentation and processes that show how a drug or medical product is made, tested for consistent quality, and kept stable from batch to batch. Investors care because strong CMC means a product can be manufactured reliably at scale and meet regulatory standards—similar to proving a recipe can be cooked the same way in any kitchen before restaurants expand—affecting approval, production costs, and potential revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentation
  • Significant reductions in body weight and food intake demonstrated in preclinical models, with encouraging preliminary cardiovascular finding
  • Proprietary lipidation technology supports once-weekly or potentially less frequent dosing; lead candidate PL2001 advancing toward first-in-human studies in the first half of 2027

PRINCETON, N.J., Nov. 16, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing differentiated, next-generation melanocortin receptor agonists, today announced the presentation of new preclinical data highlighting the Company's proprietary MC4R-selective peptide agonist programs at ObesityWeek® 2026, being held November 14–17 in Washington, D.C.

Palatin Technologies, Inc.

The findings demonstrate potent and highly selective MC4R agonist activity, significant reductions in body weight and food intake in preclinical models, and extended drug exposure through Palatin's proprietary peptide lipidation technology. Importantly, the compounds demonstrated minimal to no MC1R activity in vitro, supporting Palatin's objective of substantially reducing or potentially eliminating hyperpigmentation, a recognized limitation of currently approved MC4R therapies.

The data further support Palatin's development strategy focused on delivering potentially best-in-class MC4R agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl syndrome (BBS).

"These findings represent an important advancement in our next-generation MC4R development programs and reinforce our confidence in our ability to deliver highly differentiated therapies," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. "We have demonstrated that potent MC4R agonism and meaningful preclinical weight-loss activity can be achieved with minimal to no MC1R activity, substantially reducing or eliminating hyperpigmentation, while our proprietary lipidation technology provides the potential for once-weekly or less frequent dosing. Combined with encouraging preliminary cardiovascular findings, these results directly address several of the most important limitations of existing MC4R therapies."

Dr. Spana continued, "We believe that long-term efficacy, tolerability, and convenience will ultimately define the next generation of MC4R therapies. Our objective is not simply to replicate the benefits of existing treatments, but to meaningfully improve upon them. With PL2001 selected as a clinical development candidate and first-in-human studies targeted for the first half of 2027, we are increasingly confident in our ability to translate our differentiated preclinical science into potentially best-in-class treatments for patients with rare neuroendocrine obesity disorders."

Key Preclinical Findings Presented at ObesityWeek® 2026

Potent and highly selective MC4R agonist activity

  • Palatin's novel cyclic peptide (PL1000 series) and long-acting lipidated peptide (PL2000 series) compounds demonstrated potent activity at MC4R with minimal to no functional activity at MC1R in vitro.
  • The compounds demonstrated greater than 100-fold to greater than 200-fold selectivity for MC4R over MC1R in the reported functional assays.
  • This receptor selectivity supports the potential to substantially reduce or eliminate MC1R-mediated hyperpigmentation, a recognized adverse effect of approved MC4R agonist therapy.

Significant pre-clinical weight-loss efficacy

  • Both selective cyclic peptides and long-acting lipidated peptides demonstrated significant reductions in body weight and food intake in diet-induced obese (DIO) mice.
  • The selective peptide PL1002 demonstrated significant, dose-dependent reductions in body weight and food intake following twice-daily administration.
  • A single subcutaneous dose of the lipidated peptide PL2001 demonstrated significant, dose-dependent reductions in body weight and food intake, supporting its long-acting pharmacologic profile.

Proprietary lipidation technology supports extended duration of action

  • Palatin's proprietary lipidation approach substantially extended peptide exposure while maintaining MC4R potency and selectivity.
  • Preclinical pharmacokinetic studies demonstrated an approximately 24-hour half-life for lipidated peptides in rodents and greater than 168 hours in dogs, compared with approximately two hours for non-lipidated selective peptides.
  • These findings support the potential for once-weekly or less frequent subcutaneous administration, representing a more convenient treatment approach compared with currently approved once-daily injectable MC4R peptide therapy.

Encouraging preliminary cardiovascular findings

  • The selective peptide PL1001 demonstrated no observed effects on heart rate or blood pressure at the efficacious doses and time points evaluated in preclinical studies.
  • Additional cardiovascular safety studies are planned to further characterize the therapeutic profile of Palatin's MC4R-selective compounds.

Advancing Toward Clinical Development
Palatin has selected PL2001, a novel long-acting, lipidated, MC4R-selective peptide agonist, as a clinical development candidate. IND-enabling and chemistry, manufacturing, and controls (CMC) activities are progressing, with first-in-human studies targeted for the first half of calendar 2027 and initial clinical data anticipated in the second half of 2027.

In addition to its long-acting injectable peptide programs, Palatin continues to advance the development of orally administered MC4R-selective peptides. The Company's proprietary peptide chemistry and lipidation technology provide additional opportunities to develop compounds with improved stability and the potential for oral delivery.

Together with Palatin's complementary oral small-molecule MC4R agonist program, these development efforts provide multiple approaches to achieving the Company's objective of delivering highly differentiated, potentially best-in-class MC4R therapies.

ObesityWeek® 2026 Poster Presentation

Title: In Vitro and Preclinical Characterization of Novel Selective Melanocortin-4 Receptor Agonists
Presenter: Luipa Khandker, Ph.D.
Conference: ObesityWeek® 2026, November 14–17, 2026, Washington, D.C.
Poster Presentation Schedule: Saturday, November 14: 7:30–8:30 p.m. ET

About ObesityWeek®
ObesityWeek® is an annual international conference for obesity researchers and clinicians hosted by The Obesity Society. The conference presents developments in evidence-based obesity science, research, treatment, prevention, advocacy, and public policy. Held annually in various U.S. locations, ObesityWeek attracts over 3,200 attendees and features over 100 sessions, including lectures and presentations of scientific abstracts.

About Melanocortin-4 Receptor Agonists Effect on Obesity
Hypothalamic neurons expressing the melanocortin-4 receptor ("MC4R") play a central role in regulating stored energy, food intake and body weight. When MC4R pathway signaling is impaired, patients can experience severe hunger, reduced energy expenditure and early-onset or severe obesity. MC4R agonism represents a clinically validated therapeutic approach for obesity disorders driven by dysfunction of the melanocortin pathway.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the potential efficacy, selectivity, safety, tolerability, dosing convenience, and clinical benefits of Palatin's MC4R agonist programs; the potential to reduce or eliminate hyperpigmentation; the development of orally administered peptides; the timing of IND-enabling activities, regulatory submissions, clinical studies, and anticipated clinical data; and the potential development of best-in-class therapies. These statements are based on current expectations and assumptions and involve substantial risks and uncertainties. Preclinical findings may not predict clinical outcomes. Actual results may differ materially from those expressed or implied, including as a result of risks related to drug development, regulatory approvals, clinical trial outcomes, funding requirements, and other factors described in Palatin's filings with the Securities and Exchange Commission. Palatin undertakes no obligation to update forward-looking statements except as required by law.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-technologies-presents-compelling-preclinical-data-on-next-generation-mc4r-selective-peptide-agonists-at-obesityweek-2026-302939976.html

SOURCE Palatin Technologies, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palatin's PTN obesity drug studies show at ObesityWeek 2026?

PL1002 and PL2001 reduced body weight and food intake in diet-induced obese mice in a significant, dose-dependent manner. PL1002 was administered twice daily, while PL2001 was given as a single subcutaneous dose. These were preclinical studies.

When does Palatin expect PL2001 human studies and initial clinical data?

Palatin targets first-in-human PL2001 studies in the first half of calendar 2027 and anticipates initial clinical data in the second half of 2027. Activities needed to support investigational testing, along with chemistry, manufacturing, and controls work, are progressing.

Which obesity disorders is Palatin targeting with its MC4R programs?

Palatin's development strategy targets rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome.

Keep reading